3 results
Primary objective:To asses the safety and feasibility of post-transplant panobinostat combined with midostaurin in patients with adverse risk AML/RAEB with FLT3-ITD with high allelic ratio in terms of dose limiting toxicity.Secondary objectives:To…
Validation of the Eleveld PKPD model, both the pharmacokinetic component (plasma concentrations) and the pharmacodynamic component (effect: bispectral index (BIS) and predicted effect-site concentrations).
To compare OS between gilteritinib and midostaurin in combination with induction therapy and consolidation therapy followed by one-year maintenance therapy in patients with newly diagnosed AML with a FLT3 gene mutation eligible for intensive…